NL7201471A - - Google Patents
Info
- Publication number
- NL7201471A NL7201471A NL7201471A NL7201471A NL7201471A NL 7201471 A NL7201471 A NL 7201471A NL 7201471 A NL7201471 A NL 7201471A NL 7201471 A NL7201471 A NL 7201471A NL 7201471 A NL7201471 A NL 7201471A
- Authority
- NL
- Netherlands
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11587871A | 1971-02-16 | 1971-02-16 | |
| US25664172A | 1972-05-25 | 1972-05-25 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NL7201471A true NL7201471A (enExample) | 1972-08-18 |
| NL174349B NL174349B (nl) | 1984-01-02 |
| NL174349C NL174349C (nl) | 1984-06-01 |
Family
ID=26813670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NLAANVRAGE7201471,A NL174349C (nl) | 1971-02-16 | 1972-02-04 | Werkwijze voor de bereiding van derivaten van 2-amino-1-pyridylethanol en werkwijze voor de bereiding van preparaten die ze bevatten. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US3700681A (enExample) |
| AT (1) | AT315842B (enExample) |
| BE (1) | BE778771A (enExample) |
| CA (1) | CA978962A (enExample) |
| CH (1) | CH541560A (enExample) |
| DE (2) | DE2204195C2 (enExample) |
| FR (1) | FR2125309B1 (enExample) |
| GB (2) | GB1367669A (enExample) |
| NL (1) | NL174349C (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR207639A1 (es) * | 1973-12-26 | 1976-10-22 | Pfizer | Un procedimiento para preparar pirido (3,2-d)1,3-dioxin-6-epoxietanos y compuestos intermediarios desprovistos de actividad terapeutica |
| US3952101A (en) * | 1975-04-14 | 1976-04-20 | Smithkline Corporation | α-Amino methyl-5-hydroxy-2-pyridinemethanols |
| US4011231A (en) * | 1975-10-03 | 1977-03-08 | Pfizer Inc. | 2-Phenyl-6-(1-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin maleate and its use as an intermediate |
| SE7708307L (sv) * | 1976-08-26 | 1978-02-27 | Pfizer | Forfarande for framstellning av farmaceutiska kompositioner anvendbara sasom bronkodilatorer |
| US4175128A (en) * | 1979-01-03 | 1979-11-20 | Pfizer Inc. | Method for treating congestive heart failure |
| SU1194273A3 (ru) * | 1981-02-09 | 1985-11-23 | Пфайзер Инк (Фирма) | Способ получени пирбутерола или его аналогов |
| US4632992A (en) * | 1981-02-09 | 1986-12-30 | Pfizer Inc. | Intermediates for preparing pirbuterol and analogs |
| GB8414559D0 (en) * | 1984-06-07 | 1984-07-11 | Scras | Pyridine derivatives |
| EP0220054A3 (en) * | 1985-10-16 | 1987-12-02 | Glaxo Group Limited | Ethanolamine derivatives |
| US4601897A (en) * | 1985-11-06 | 1986-07-22 | Pfizer Inc. | Prazosin-pirbuterol combination for bronchodilation |
| WO1993000090A1 (en) * | 1991-06-26 | 1993-01-07 | Sepracor, Inc. | Methods and compositions for treating pulmonary and cardiac disorders using optically pure (+) pirbuterol |
| WO1993000091A1 (en) * | 1991-06-26 | 1993-01-07 | Sepracor, Inc. | Methods and compositions for treating pulmonary and cardiac disorders using optically pure (-)pirbuterol |
| US7101534B1 (en) | 1991-12-18 | 2006-09-05 | 3M Innovative Properties Company | Suspension aerosol formulations |
| US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| US7825147B2 (en) * | 2003-08-29 | 2010-11-02 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV |
| US20070259874A1 (en) * | 2003-11-26 | 2007-11-08 | Palle Venkata P | Phosphodiesterase Inhibitors |
| WO2005092860A1 (en) * | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds for the treatment of diseases |
| US7915286B2 (en) | 2005-09-16 | 2011-03-29 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
| WO2007045979A1 (en) | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of muscarinic receptor antagonists |
| BRPI0617673C1 (pt) * | 2005-10-19 | 2012-05-22 | Ranbaxy Lab Ltd | composições de inibidores de fosfodiesterase do tipo iv |
| WO2008023336A2 (en) | 2006-08-22 | 2008-02-28 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
| WO2008035315A2 (en) * | 2006-09-22 | 2008-03-27 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
| EP2066661A2 (en) * | 2006-09-22 | 2009-06-10 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
| EP1958947A1 (en) | 2007-02-15 | 2008-08-20 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type 4 |
| US20110130403A1 (en) * | 2007-03-14 | 2011-06-02 | Ranbaxy Laboratories Limited | Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors |
| DK2124944T3 (da) | 2007-03-14 | 2012-04-23 | Ranbaxy Lab Ltd | Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer |
| EP2111861A1 (en) | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
| MX2013001240A (es) | 2010-07-30 | 2013-08-27 | Ranbaxy Lab Ltd | Inhibidores de metaloproteinas de matriz. |
| CN103228634A (zh) | 2010-09-24 | 2013-07-31 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
| CN103848781B (zh) * | 2012-11-30 | 2017-06-30 | 重庆华邦制药有限公司 | 高选择性氧化二羟甲基吡啶中一个羟甲基的方法 |
| WO2014087298A1 (en) | 2012-12-03 | 2014-06-12 | Pfizer Inc. | Novel selective androgen receptor modulators |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1089189A (en) * | 1964-09-23 | 1967-11-01 | Koninklijke Pharma Fab Nv | Ethers of -(2-pyridyl)benzyl alcohols |
-
1971
- 1971-02-16 US US115878A patent/US3700681A/en not_active Expired - Lifetime
- 1971-11-04 GB GB3749773A patent/GB1367669A/en not_active Expired
- 1971-11-04 GB GB5141671A patent/GB1367668A/en not_active Expired
-
1972
- 1972-01-27 AT AT63972A patent/AT315842B/de not_active IP Right Cessation
- 1972-01-29 DE DE2204195A patent/DE2204195C2/de not_active Expired
- 1972-01-29 DE DE2265581A patent/DE2265581C2/de not_active Expired
- 1972-02-01 BE BE778771A patent/BE778771A/xx not_active IP Right Cessation
- 1972-02-02 FR FR7203470A patent/FR2125309B1/fr not_active Expired
- 1972-02-03 CA CA133,875A patent/CA978962A/en not_active Expired
- 1972-02-04 CH CH164872A patent/CH541560A/fr not_active IP Right Cessation
- 1972-02-04 NL NLAANVRAGE7201471,A patent/NL174349C/xx not_active IP Right Cessation
- 1972-05-25 US US00256641A patent/US3763173A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US3700681A (en) | 1972-10-24 |
| CA978962A (en) | 1975-12-02 |
| AT315842B (de) | 1974-06-10 |
| CH541560A (fr) | 1973-10-31 |
| GB1367669A (en) | 1974-09-18 |
| DE2204195C2 (de) | 1981-11-19 |
| US3763173A (en) | 1973-10-02 |
| NL174349C (nl) | 1984-06-01 |
| DE2265581C2 (de) | 1982-07-01 |
| GB1367668A (en) | 1974-09-18 |
| DE2204195A1 (de) | 1972-08-17 |
| NL174349B (nl) | 1984-01-02 |
| FR2125309B1 (enExample) | 1976-05-14 |
| FR2125309A1 (enExample) | 1972-09-29 |
| BE778771A (fr) | 1972-08-01 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| V4 | Discontinued because of reaching the maximum lifetime of a patent |